Intervention Review

You have free access to this content

Pharmacological treatment for memory disorder in multiple sclerosis

  1. Dian He1,
  2. Yun Zhang2,
  3. Shuai Dong3,
  4. Dongfeng Wang3,
  5. Xiangdong Gao3,
  6. Hongyu Zhou4,*

Editorial Group: Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group

Published Online: 17 DEC 2013

Assessed as up-to-date: 25 JUL 2013

DOI: 10.1002/14651858.CD008876.pub3


How to Cite

He D, Zhang Y, Dong S, Wang D, Gao X, Zhou H. Pharmacological treatment for memory disorder in multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD008876. DOI: 10.1002/14651858.CD008876.pub3.

Author Information

  1. 1

    Affiliated Hospital of Guiyang Medical College, Department of Neurology, Guiyang, Guizhou Province, China

  2. 2

    Jinan No. 6 People's Hospital, Clinical Laboratory, Jinan, Shandong Province, China

  3. 3

    Jinan No. 6 People's Hospital, Department of Neurology, Jinan, Shandong Province, China

  4. 4

    West China Hospital, Sichuan University, Department of Neurology, Chengdu, Sichuan, China

*Hongyu Zhou, Department of Neurology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, China. Hyzhou98@yahoo.com.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 17 DEC 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 4]
Figure 4. Efficacy on the primary outcomes reported in each study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Subgroup analysis for donepezil versus placebo, Outcome 1 The mean change of total recall on the Selective Reminding Test (SRT) from baseline.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Subgroup analysis for donepezil versus placebo, Outcome 2 The mean total recall on the Selective Reminding Test (SRT) at exit.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Subgroup analysis for donepezil versus placebo, Outcome 3 The mean change of total correct score on the 10/36 Spatial Recall Test (10/36 SRT) from baseline.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Subgroup analysis for donepezil versus placebo, Outcome 4 The mean total correct score on the 10/36 Spatial Recall Test (10/36 SRT) at exit.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Subgroup analysis for donepezil versus placebo, Outcome 5 The mean change of total correct score on the Symbol Digit Modalities Test (SDMT) from baseline.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Subgroup analysis for donepezil versus placebo, Outcome 6 The mean total correct score on the Symbol Digit Modalities Test (SDMT) at exit.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Subgroup analysis for donepezil versus placebo, Outcome 7 The mean change of total correct score on the Paced Auditory Serial Addition Test (PASAT) (2+3 sec) from baseline.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Subgroup analysis for donepezil versus placebo, Outcome 8 The mean total correct score on the Paced Auditory Serial Addition Test (PASAT) (2+3 sec) at exit.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Subgroup analysis for donepezil versus placebo, Outcome 9 The number of patients experiencing diarrhoea.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Subgroup analysis for donepezil versus placebo, Outcome 10 The number of patients experiencing diarrhoea.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Subgroup analysis for donepezil versus placebo, Outcome 11 The number of patients experiencing nausea.
[Analysis 1.12]
Analysis 1.12. Comparison 1 Subgroup analysis for donepezil versus placebo, Outcome 12 The number of patients experiencing nausea.
[Analysis 1.13]
Analysis 1.13. Comparison 1 Subgroup analysis for donepezil versus placebo, Outcome 13 The number of patients experiencing abnormal dreams.
[Analysis 1.14]
Analysis 1.14. Comparison 1 Subgroup analysis for donepezil versus placebo, Outcome 14 The number of patients experiencing abnormal dreams.